Reports

Industry Research Reports

description

Part 1

description

Part 2

description

Part 3

description

Part 5

Global and United States CD47 (IAP) Market Report & Forecast 2022-2028

Global and United States CD47 (IAP) Market Report & Forecast 2022-2028

Industry: Pharma & Healthcare

Published: 2022-04-23

Pages: 114 Pages

Report ld: 352059

  • Description 选中
  • Table of Contents 选中
  • Table of Figures 选中
  • PDF PDF Download 选中
  • Description 选中
  • Table of Contents 选中
  • Table of Figures 选中
  • PDF PDF Download 选中
Market Analysis and Insights: Global and United States CD47 (IAP) Market
This report focuses on global and United States CD47 (IAP) market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global CD47 (IAP) market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, CD47 Monoclonal Antibody accounting for % of the CD47 (IAP) global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Solid Tumor was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the CD47 (IAP) market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global CD47 (IAP) Scope and Market Size
CD47 (IAP) market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global CD47 (IAP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the CD47 (IAP) market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    CD47 Monoclonal Antibody
    CD47 Double Antibody
    CD47 Fusion Protein

Segment by Application
    Solid Tumor
    Lymphoma
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Gilead
    Innovent Biologics
    Akeso, Inc
    Arch Oncology
    ImmuneOncia Therapeutics
    I-MAB
    Sorrento Therapeutics
    Zai Lab
    ImmuneOnco
    Hengrui
    Beijing Mab-works
    Hanxbio
    ALX Oncology
    Surface Oncology
    TG Therapeutics
    EpicentRx
 1 Study Coverage
1.1 CD47 (IAP) Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Introduction
1.2 Global CD47 (IAP) Outlook 2017 VS 2022 VS 2028
1.2.1 Global CD47 (IAP) Market Size for the Year 2017-2028
1.2.2 Global CD47 (IAP) Market Size for the Year 2017-2028
1.3 CD47 (IAP) Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States CD47 (IAP) in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of CD47 (IAP) Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 CD47 (IAP) Market Dynamics
1.4.1 CD47 (IAP) Industry Trends
1.4.2 CD47 (IAP) Market Drivers
1.4.3 CD47 (IAP) Market Challenges
1.4.4 CD47 (IAP) Market Restraints
1.5 Study Objectives
1.6 Years Considered

 2 CD47 (IAP) by Type
2.1 CD47 (IAP) Market Segment by Type
2.1.1 CD47 Monoclonal Antibody
2.1.2 CD47 Double Antibody
2.1.3 CD47 Fusion Protein
2.2 Global CD47 (IAP) Market Size by Type (2017, 2022 & 2028)
2.3 Global CD47 (IAP) Market Size by Type (2017-2028)
2.4 United States CD47 (IAP) Market Size by Type (2017, 2022 & 2028)
2.5 United States CD47 (IAP) Market Size by Type (2017-2028)

 3 CD47 (IAP) by Application
3.1 CD47 (IAP) Market Segment by Application
3.1.1 Solid Tumor
3.1.2 Lymphoma
3.1.3 Others
3.2 Global CD47 (IAP) Market Size by Application (2017, 2022 & 2028)
3.3 Global CD47 (IAP) Market Size by Application (2017-2028)
3.4 United States CD47 (IAP) Market Size by Application (2017, 2022 & 2028)
3.5 United States CD47 (IAP) Market Size by Application (2017-2028)

 4 Global CD47 (IAP) Competitor Landscape by Company
4.1 Global CD47 (IAP) Market Size by Company
4.1.1 Top Global CD47 (IAP) Companies Ranked by Revenue (2021)
4.1.2 Global CD47 (IAP) Revenue by Player (2017-2022)
4.2 Global CD47 (IAP) Concentration Ratio (CR)
4.2.1 CD47 (IAP) Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of CD47 (IAP) in 2021
4.2.3 Global CD47 (IAP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global CD47 (IAP) Headquarters, Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Type
4.3.1 Global CD47 (IAP) Headquarters and Area Served
4.3.2 Global CD47 (IAP) Companies Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into CD47 (IAP) Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States CD47 (IAP) Market Size by Company
4.5.1 Top CD47 (IAP) Players in United States, Ranked by Revenue (2021)
4.5.2 United States CD47 (IAP) Revenue by Players (2020, 2021 & 2022)

 5 Global CD47 (IAP) Market Size by Region
5.1 Global CD47 (IAP) Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global CD47 (IAP) Market Size by Region (2017-2028)
5.2.1 Global CD47 (IAP) Market Size by Region: 2017-2022
5.2.2 Global CD47 (IAP) Market Size by Region (2023-2028)

 6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America CD47 (IAP) Market Size YoY Growth 2017-2028
6.1.2 North America CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific CD47 (IAP) Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific CD47 (IAP) Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe CD47 (IAP) Market Size YoY Growth 2017-2028
6.3.2 Europe CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America CD47 (IAP) Market Size YoY Growth 2017-2028
6.4.2 Latin America CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa CD47 (IAP) Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa CD47 (IAP) Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE

 7 Company Profiles
7.1 Gilead
7.1.1 Gilead Company Details
7.1.2 Gilead Business Overview
7.1.3 Gilead CD47 (IAP) Introduction
7.1.4 Gilead Revenue in CD47 (IAP) Business (2017-2022)
7.1.5 Gilead Recent Development
7.2 Innovent Biologics
7.2.1 Innovent Biologics Company Details
7.2.2 Innovent Biologics Business Overview
7.2.3 Innovent Biologics CD47 (IAP) Introduction
7.2.4 Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022)
7.2.5 Innovent Biologics Recent Development
7.3 Akeso, Inc
7.3.1 Akeso, Inc Company Details
7.3.2 Akeso, Inc Business Overview
7.3.3 Akeso, Inc CD47 (IAP) Introduction
7.3.4 Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022)
7.3.5 Akeso, Inc Recent Development
7.4 Arch Oncology
7.4.1 Arch Oncology Company Details
7.4.2 Arch Oncology Business Overview
7.4.3 Arch Oncology CD47 (IAP) Introduction
7.4.4 Arch Oncology Revenue in CD47 (IAP) Business (2017-2022)
7.4.5 Arch Oncology Recent Development
7.5 ImmuneOncia Therapeutics
7.5.1 ImmuneOncia Therapeutics Company Details
7.5.2 ImmuneOncia Therapeutics Business Overview
7.5.3 ImmuneOncia Therapeutics CD47 (IAP) Introduction
7.5.4 ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
7.5.5 ImmuneOncia Therapeutics Recent Development
7.6 I-MAB
7.6.1 I-MAB Company Details
7.6.2 I-MAB Business Overview
7.6.3 I-MAB CD47 (IAP) Introduction
7.6.4 I-MAB Revenue in CD47 (IAP) Business (2017-2022)
7.6.5 I-MAB Recent Development
7.7 Sorrento Therapeutics
7.7.1 Sorrento Therapeutics Company Details
7.7.2 Sorrento Therapeutics Business Overview
7.7.3 Sorrento Therapeutics CD47 (IAP) Introduction
7.7.4 Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
7.7.5 Sorrento Therapeutics Recent Development
7.8 Zai Lab
7.8.1 Zai Lab Company Details
7.8.2 Zai Lab Business Overview
7.8.3 Zai Lab CD47 (IAP) Introduction
7.8.4 Zai Lab Revenue in CD47 (IAP) Business (2017-2022)
7.8.5 Zai Lab Recent Development
7.9 ImmuneOnco
7.9.1 ImmuneOnco Company Details
7.9.2 ImmuneOnco Business Overview
7.9.3 ImmuneOnco CD47 (IAP) Introduction
7.9.4 ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022)
7.9.5 ImmuneOnco Recent Development
7.10 Hengrui
7.10.1 Hengrui Company Details
7.10.2 Hengrui Business Overview
7.10.3 Hengrui CD47 (IAP) Introduction
7.10.4 Hengrui Revenue in CD47 (IAP) Business (2017-2022)
7.10.5 Hengrui Recent Development
7.11 Beijing Mab-works
7.11.1 Beijing Mab-works Company Details
7.11.2 Beijing Mab-works Business Overview
7.11.3 Beijing Mab-works CD47 (IAP) Introduction
7.11.4 Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022)
7.11.5 Beijing Mab-works Recent Development
7.12 Hanxbio
7.12.1 Hanxbio Company Details
7.12.2 Hanxbio Business Overview
7.12.3 Hanxbio CD47 (IAP) Introduction
7.12.4 Hanxbio Revenue in CD47 (IAP) Business (2017-2022)
7.12.5 Hanxbio Recent Development
7.13 ALX Oncology
7.13.1 ALX Oncology Company Details
7.13.2 ALX Oncology Business Overview
7.13.3 ALX Oncology CD47 (IAP) Introduction
7.13.4 ALX Oncology Revenue in CD47 (IAP) Business (2017-2022)
7.13.5 ALX Oncology Recent Development
7.14 Surface Oncology
7.14.1 Surface Oncology Company Details
7.14.2 Surface Oncology Business Overview
7.14.3 Surface Oncology CD47 (IAP) Introduction
7.14.4 Surface Oncology Revenue in CD47 (IAP) Business (2017-2022)
7.14.5 Surface Oncology Recent Development
7.15 TG Therapeutics
7.15.1 TG Therapeutics Company Details
7.15.2 TG Therapeutics Business Overview
7.15.3 TG Therapeutics CD47 (IAP) Introduction
7.15.4 TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022)
7.15.5 TG Therapeutics Recent Development
7.16 EpicentRx
7.16.1 EpicentRx Company Details
7.16.2 EpicentRx Business Overview
7.16.3 EpicentRx CD47 (IAP) Introduction
7.16.4 EpicentRx Revenue in CD47 (IAP) Business (2017-2022)
7.16.5 EpicentRx Recent Development

 8 Research Findings and Conclusion

 9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
List of Tables
    Table 1. CD47 (IAP) Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. CD47 (IAP) Market Trends
    Table 3. CD47 (IAP) Market Drivers
    Table 4. CD47 (IAP) Market Challenges
    Table 5. CD47 (IAP) Market Restraints
    Table 6. Global CD47 (IAP) Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States CD47 (IAP) Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global CD47 (IAP) Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States CD47 (IAP) Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top CD47 (IAP) Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global CD47 (IAP) Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global CD47 (IAP) Revenue Share by Player, 2017-2022
    Table 13. Global CD47 (IAP) Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global CD47 (IAP) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CD47 (IAP) as of 2021)
    Table 15. Top Players of CD47 (IAP) in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into CD47 (IAP) Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top CD47 (IAP) Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States CD47 (IAP) Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States CD47 (IAP) Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global CD47 (IAP) Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global CD47 (IAP) Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global CD47 (IAP) Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America CD47 (IAP) Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific CD47 (IAP) Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe CD47 (IAP) Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa CD47 (IAP) Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa CD47 (IAP) Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Gilead Company Details
    Table 31. Gilead Business Overview
    Table 32. Gilead CD47 (IAP) Product
    Table 33. Gilead Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 34. Gilead Recent Development
    Table 35. Innovent Biologics Company Details
    Table 36. Innovent Biologics Business Overview
    Table 37. Innovent Biologics CD47 (IAP) Product
    Table 38. Innovent Biologics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 39. Innovent Biologics Recent Development
    Table 40. Akeso, Inc Company Details
    Table 41. Akeso, Inc Business Overview
    Table 42. Akeso, Inc CD47 (IAP) Product
    Table 43. Akeso, Inc Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 44. Akeso, Inc Recent Development
    Table 45. Arch Oncology Company Details
    Table 46. Arch Oncology Business Overview
    Table 47. Arch Oncology CD47 (IAP) Product
    Table 48. Arch Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 49. Arch Oncology Recent Development
    Table 50. ImmuneOncia Therapeutics Company Details
    Table 51. ImmuneOncia Therapeutics Business Overview
    Table 52. ImmuneOncia Therapeutics CD47 (IAP) Product
    Table 53. ImmuneOncia Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 54. ImmuneOncia Therapeutics Recent Development
    Table 55. I-MAB Company Details
    Table 56. I-MAB Business Overview
    Table 57. I-MAB CD47 (IAP) Product
    Table 58. I-MAB Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 59. I-MAB Recent Development
    Table 60. Sorrento Therapeutics Company Details
    Table 61. Sorrento Therapeutics Business Overview
    Table 62. Sorrento Therapeutics CD47 (IAP) Product
    Table 63. Sorrento Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 64. Sorrento Therapeutics Recent Development
    Table 65. Zai Lab Company Details
    Table 66. Zai Lab Business Overview
    Table 67. Zai Lab CD47 (IAP) Product
    Table 68. Zai Lab Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 69. Zai Lab Recent Development
    Table 70. ImmuneOnco Company Details
    Table 71. ImmuneOnco Business Overview
    Table 72. ImmuneOnco CD47 (IAP) Product
    Table 73. ImmuneOnco Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 74. ImmuneOnco Recent Development
    Table 75. Hengrui Company Details
    Table 76. Hengrui Business Overview
    Table 77. Hengrui CD47 (IAP) Product
    Table 78. Hengrui Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 79. Hengrui Recent Development
    Table 80. Beijing Mab-works Company Details
    Table 81. Beijing Mab-works Business Overview
    Table 82. Beijing Mab-works CD47 (IAP) Product
    Table 83. Beijing Mab-works Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 84. Beijing Mab-works Recent Development
    Table 85. Hanxbio Company Details
    Table 86. Hanxbio Business Overview
    Table 87. Hanxbio CD47 (IAP) Product
    Table 88. Hanxbio Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 89. Hanxbio Recent Development
    Table 90. ALX Oncology Company Details
    Table 91. ALX Oncology Business Overview
    Table 92. ALX Oncology CD47 (IAP) Product
    Table 93. ALX Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 94. ALX Oncology Recent Development
    Table 95. Surface Oncology Company Details
    Table 96. Surface Oncology Business Overview
    Table 97. Surface Oncology CD47 (IAP) Product
    Table 98. Surface Oncology Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 99. Surface Oncology Recent Development
    Table 100. TG Therapeutics Company Details
    Table 101. TG Therapeutics Business Overview
    Table 102. TG Therapeutics CD47 (IAP) Product
    Table 103. TG Therapeutics Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 104. TG Therapeutics Recent Development
    Table 105. EpicentRx Company Details
    Table 106. EpicentRx Business Overview
    Table 107. EpicentRx CD47 (IAP) Product
    Table 108. EpicentRx Revenue in CD47 (IAP) Business (2017-2022) & (US$ Million)
    Table 109. EpicentRx Recent Development
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
List of Figures
    Figure 1. CD47 (IAP) Product Picture
    Figure 2. Global CD47 (IAP) Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global CD47 (IAP) Market Size 2017-2028 (US$ Million)
    Figure 4. United States CD47 (IAP) Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States CD47 (IAP) Market Size 2017-2028 (US$ Million)
    Figure 6. United States CD47 (IAP) Market Share in Global 2017-2028
    Figure 7. CD47 (IAP) Report Years Considered
    Figure 8. Product Picture of CD47 Monoclonal Antibody
    Figure 9. Product Picture of CD47 Double Antibody
    Figure 10. Product Picture of CD47 Fusion Protein
    Figure 11. Global CD47 (IAP) Market Share by Type in 2022 & 2028
    Figure 12. Global CD47 (IAP) Market Size by Type (2017-2028) & (US$ Million)
    Figure 13. Global CD47 (IAP) Market Share by Type (2017-2028)
    Figure 14. United States CD47 (IAP) Market Share by Type in 2022 & 2028
    Figure 15. United States CD47 (IAP) Market Size by Type (2017-2028) & (US$ Million)
    Figure 16. United States CD47 (IAP) Market Share by Type (2017-2028)
    Figure 17. Product Picture of Solid Tumor
    Figure 18. Product Picture of Lymphoma
    Figure 19. Product Picture of Others
    Figure 20. Global CD47 (IAP) Market Share by Application in 2022 & 2028
    Figure 21. Global CD47 (IAP) Market Size by Application (2017-2028) & (US$ Million)
    Figure 22. Global CD47 (IAP) Market Share by Application (2017-2028)
    Figure 23. United States CD47 (IAP) Market Share by Application in 2022 & 2028
    Figure 24. United States CD47 (IAP) Market Size by Application (2017-2028) & (US$ Million)
    Figure 25. United States CD47 (IAP) Market Share by Application (2017-2028)
    Figure 26. North America CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 27. United States CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 28. Canada CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Europe CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 30. Germany CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. France CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. U.K. CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Italy CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Russia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Asia-Pacific CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 36. China CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Japan CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. South Korea CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. India CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Australia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. China Taiwan CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Indonesia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Thailand CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Malaysia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Latin America CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 46. Mexico CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Brazil CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Argentina CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Middle East & Africa CD47 (IAP) Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 50. Turkey CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Saudi Arabia CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. UAE CD47 (IAP) Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Gilead Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 54. Innovent Biologics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 55. Akeso, Inc Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 56. Arch Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 57. ImmuneOncia Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 58. I-MAB Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 59. Sorrento Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 60. Zai Lab Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 61. ImmuneOnco Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 62. Hengrui Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 63. Beijing Mab-works Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 64. Hanxbio Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 65. ALX Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 66. Surface Oncology Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 67. TG Therapeutics Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 68. EpicentRx Revenue Growth Rate in CD47 (IAP) Business (2017-2022)
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed
Market Analysis and Insights: Global and United States CD47 (IAP) Market
This report focuses on global and United States CD47 (IAP) market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global CD47 (IAP) market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, CD47 Monoclonal Antibody accounting for % of the CD47 (IAP) global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Solid Tumor was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the CD47 (IAP) market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global CD47 (IAP) Scope and Market Size
CD47 (IAP) market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global CD47 (IAP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the CD47 (IAP) market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    CD47 Monoclonal Antibody
    CD47 Double Antibody
    CD47 Fusion Protein

Segment by Application
    Solid Tumor
    Lymphoma
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Gilead
    Innovent Biologics
    Akeso, Inc
    Arch Oncology
    ImmuneOncia Therapeutics
    I-MAB
    Sorrento Therapeutics
    Zai Lab
    ImmuneOnco
    Hengrui
    Beijing Mab-works
    Hanxbio
    ALX Oncology
    Surface Oncology
    TG Therapeutics
    EpicentRx
    
Global and United States CD47 (IAP) Market Report & Forecast 2022-2028

Industry: Pharma & Healthcare

Published: 2022-04-23

Pages: 114 Pages

Report ld: 352059

CHOOSE LICENSE TYPE
提示

USD 4350.00

提示

USD 6525.00

提示

USD 8700.00

/uploads/payment/payIcon/masterCard-01.svg/uploads/payment/payIcon/american-express-01.svg/uploads/payment/payIcon/visa-01.svg/uploads/payment/payIcon/diners-club-01.svg/uploads/payment/payIcon/discover-4-01.svg/uploads/payment/payIcon/jcb-01.svg
加入购物车

Add to Cart

立即购买

Buy Now

A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.

WHAT QYRESEARCH OFFER?
Competition

Competition

Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.

Industry Analysis

Industry Analysis

Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.

Market Size

Market Size

Capacity, production, sales, revenue, price, cost etc.

Customized Information

Customized Information

We can offer customized survey and information to meet ourclient's need.

INTEREST IN THIS REPORT?

Get A Free Sample >>
WHY QYR?
  • Fastest report delivery service

    Fastest report delivery service

  • More than 17 years of vast experience

    More than 17 years of vast experience

  • Operation for 24 * 7 & 365 days

    Operation for 24 * 7 & 365 days

  • In-depth and comprehensive analysis

    In-depth and comprehensive analysis

  • Professional and timely after-sales service

    Professional and timely after-sales service

  • Owns large database

    Owns large database

A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.

WHAT QYRESEARCH OFFER?
Competition

Competition

Key players, new entrants,acquisitions, mergers and expansions,development trends and challenges.

Industry Analysis

Industry Analysis

Rawmaterial, application, product type, demand,supply,downstream, supply chain etc.

Market Size

Market Size

Capacity, production, sales, revenue, price, cost etc.

Customized Information

Customized Information

We can offer customized survey and information to meet ourclient's need.

INTEREST IN THIS REPORT?

Get A Free Sample >>
WHY QYR?
  • Fastest report delivery service

    Fastest report delivery service

  • More than 17 years of vast experience

    More than 17 years of vast experience

  • Operation for 24 * 7 & 365 days

    Operation for 24 * 7 & 365 days

  • In-depth and comprehensive analysis

    In-depth and comprehensive analysis

  • Professional and timely after-sales service

    Professional and timely after-sales service

  • Owns large database

    Owns large database

biaoTi

WORLD WIDE OFFICE

加入购物车

Add to Cart

立即购买

Buy Now